Tempramed launches products in Israel's Super-Pharm

Executive Summary

• Tempramed Technologies has commenced a national product rollout of its temperature-protection portfolio across Super-Pharm, Israel's largest pharmacy and health-retail chain.
• This expansion marks a significant commercialization milestone, increasing visibility and point-of-care access for patients managing temperature-sensitive medications such as insulin and epinephrine auto-injectors.
• The partnership reinforces Tempramed's multichannel distribution strategy, complementing recent expansions with Maccabi Pharm and positioning Israel as a strategic validation market for broader international expansion in Europe and North America.

Key Details

• Partnership: Tempramed Technologies partnered with Super-Pharm, Israel's leading pharmacy chain, to roll out its products nationally.
• Product Portfolio: The rollout includes Tempramed's temperature-protection products designed for patients managing insulin, epinephrine auto-injectors, and other temperature-sensitive medications.
• Strategic Impact: The deal significantly increases consumer reach, providing access to millions of potential customers across Israel and large HMO (Health Maintenance Organization) customers.
• Distribution Strategy: The Super-Pharm placement complements Tempramed's defined multichannel strategy, which includes:
  • Global health care payors, networks, and HMOs.
  • National retail pharmacy chains in core markets.
  • Online and direct-to-consumer platforms.
• Market Validation: Israel is viewed as a strategic launch and validation market for broader international expansion, with successful retail rollouts serving as a blueprint for partnerships in Europe, North America, and other high-growth regions.
• Previous Expansions: This rollout follows a recent expansion to Maccabi Pharm, providing adoption support from two significant national pharmacy chains.

Notable Quotes

• "This is an exciting inflection point for Tempramed, as we continue to execute on our defined commercialization strategy in Israel, a core market for us and as well globally," said Ron Nagar, chief executive officer of Tempramed. "Super-Pharm is a cornerstone of health care in Israel and rolling out our products to Super-Pharm substantially expands our consumer reach and reinforces Tempramed's position as the category leader in personal medication temperature protection and management. This is another step in executing our strategy to scale through high-traffic retail and health care channels. We will now have access to millions of potential customers across Israel through our national pharmacy rollout strategy as well as access to large HMO customers."